Dr Max Søgaard | Director of Process Development
Expres2Ion Biotechnologies | Denmark

Dr Max Søgaard, Director of Process Development, Expres2Ion Biotechnologies

Following post-doctoral work in protein crystallography at University of Oxford, Max Søgaard joined Expres2ion Biotechnologies in 2013.  Working closely with clients he has helped to convert non-cGMP, lab-scale protocols into fully scalable, reproducible, cGMP compliant processes in a number of projects currently in clinical phase I/II trials.  His current focus is to expand the up- and downstream capabilities of the Expres2ion Biotechnologies protein production platform to meet the individual and diverse challenges of proteins for vaccine-antigens, diagnostics and therapeutics.  His pre-doctoral focus was within the field of basal transcription (Ph.D., Clare Hall, Cancer Research UK) as well as basal translation (Cand.Scient, University of Aarhus, Denmark).

Appearances:



DC Co-conference Day 2 April 4 @ 12:25

ExpreS2 – an insect cell based vaccine production system suitable for difficult-to-express proteins

back to speakers